Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Deferred Revenue (2016 - 2020)

Amicus Therapeutics filings provide 8 years of Current Deferred Revenue readings, the most recent being $1.2 million for Q1 2020.

  • On a quarterly basis, Current Deferred Revenue fell 54.55% to $1.2 million in Q1 2020 year-over-year; TTM through Mar 2020 was $1.2 million, a 54.55% decrease, with the full-year FY2019 number at $1.2 million, down 77.27% from a year prior.
  • Current Deferred Revenue hit $1.2 million in Q1 2020 for Amicus Therapeutics, roughly flat from $1.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $18.8 million in Q2 2017 to a low of $1.2 million in Q4 2019.
  • Median Current Deferred Revenue over the past 5 years was $5.4 million (2018), compared with a mean of $6.6 million.
  • Biggest five-year swings in Current Deferred Revenue: crashed 85.41% in 2018 and later skyrocketed 90.91% in 2019.
  • Amicus Therapeutics' Current Deferred Revenue stood at $13.8 million in 2016, then tumbled by 44.04% to $7.8 million in 2017, then dropped by 29.03% to $5.5 million in 2018, then plummeted by 77.27% to $1.2 million in 2019, then changed by 0.0% to $1.2 million in 2020.
  • The last three reported values for Current Deferred Revenue were $1.2 million (Q1 2020), $1.2 million (Q4 2019), and $5.2 million (Q3 2019) per Business Quant data.